Skip to main content
OpenTrials
Completed

NCT Number: NCT06392243

IntraCardiac Echocardiography sysTem

To evaluate the safety and effectiveness of intracardiac ultrasound imaging system in Sonosemi Medical Co., Ltd.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sonosemi Medical Co., Ltd.

Shenzhen, Guangdong, China

About this study

A prospective, multicenter, randomized controlled, non-inferiority clinical trial was designed. In the experimental group, intracardiac and large blood vessel imaging, intracardiac Doppler flow assessment and guidance of intracardiac intervention were performed by intracardiac ultrasound imaging system of Sonosemi Medical Co., Ltd. The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention. After meeting the entry criteria, they will be randomized by an electronic randomization system, and the researchers will conduct a clinical trial based on the results of the randomization, intracardiac and large vessel imaging, intracardiac Doppler flow assessment, and guidance of intracardiac intervention were performed in both groups

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients aged ≥18 years and ≤85 years, regardless of gender,
  • patients who planned to undergo intracardiac and macrovascular imaging, intracardiac Doppler flow assessment, and intracardiac intervention,
  • subjects who could understand the purpose of the trial, were willing to cooperate with interventional treatment and follow-up, participated in the trial voluntarily and signed a written informed consent.

Exclusion criteria

  • known complication of sepsis, thrombosis or severe peripheral vascular disease;
  • angina class IV CCS or NYHA Class IV cardiac function,
  • severe Coagulopathy unable to perform vascular puncture,
  • known to be severely allergic to the materials used in the study;
  • pregnant or lactating women, or those who had planned to become pregnant during the trial;
  • those who were enrolled in any other drug or medical device clinical trial and had not yet left the group;
  • other conditions that the investigator judged unsuitable for enrollment.

Treatment and study plan

Intracardiac ultrasound imaging system

Device

The control group was treated with SOUNDSTAR 3D Diagnostic Ultrasound catheter (SNDSTR10G) and Vivid IQ, intracardiac and macrovascular imaging of the heart, assessment of intracardiac Doppler flow, and guidance for intracardiac intervention

Primary outcomes

  1. Excellent rate of image

    Time frame: 0 days after the operation

    In intracardiac and large-vessel endocardial imaging of the heart, the researchers determined the ratio of"Excellent" to"Good" ultrasound image quality

Sponsors and collaborators

Lead sponsor

Sonosemi Medical Co., Ltd.

Other

Registry information

Official study title

Prospective, Multicenter, ranDomized Controlled, Non-Inferior Clinical Trial to Evaluate the SafeTy and effIcacy of a Novel intraCardiac Echocardiography sysTem(DISTINCT Trial)

Acronym: DISTINCT

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 30, 2024
Registry last updated
Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.